Depressive Disorder
•
•
Review this week’s Learning Resources, including the Medication Resources
indicated for this week.
Reflect on the psychopharmacologic treatments you might recommend for the
assessment and treatment of vulnerable patient populations requiring
antidepressant therapy.
For this assignment, you will develop a patient medication guide for treatment of
depressive disorders in a vulnerable population (your choice for one vulnerable patient
population to choose from: children, adolescents, older adults, dementia patients,
pregnant women or one not listed of your choice!). Be sure to use language appropriate
for your audience (patient, caregiver, parent, etc.). You will include non-copyright images
and/or information tables to make your patient medication guide interesting and
appealing. Limit your patient medication guide to 4-5 pages. You will create this guide as
an assignment; therefore, a title page, introduction, conclusion, and reference page are
required. You must include a minimum of 3 scholarly supporting resources outside of
your course provided resources.
In your patient guide, include discussion on the following:
•
•
•
•
•
•
•
•
Depressive disorder causes and symptoms
How depression is diagnosed for the vulnerable population of your choice,
why is this population considered vulnerable
Medication treatment options including risk vs benefits; side effects; FDA
approvals for the vulnerable population of your choice
Medication considerations of medication examples prescribed (see last bullet
item)
What is important to monitor in terms of labs, comorbid medical issues with
why important for monitoring
Special Considerations (you must be specific, not general and address at least
one for EACH category; you must demonstrate critical thinking beyond basics
of HIPPA and informed consent!): legal considerations, ethical considerations,
cultural considerations, social determinants of health
Where to follow up in your local community for further information
Provide 3 examples of how to write a proper prescription that you would
provide to the patient or transmit to the pharmacy.
Note: Support your rationale with a minimum of five academic resources. While you may
use the course text to support your rationale, it will not count toward the resource
requirement. You should be utilizing the primary and secondary literature.
Reminder: The College of Nursing requires that all papers submitted include a title page,
introduction, summary, and references. The Sample Paper provided at the Walden
Writing CenterLinks to an external site. provides an example of those required elements
(available at https://academicguides.waldenu.edu/writingcenter/templates/general#s-lgbox-20293632)Links to an external site.. All papers submitted must use this formatting.
•
•
•
•
•
•
•
•
•
Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific
basis and practical applications (5th Ed.) Cambridge University Press.
o Chapter 6, “Mood Disorders and the Neurotransmitter Networks
Norepinephrine and y-Aminobutyric Acid (GABA)” (pp. 244-282)
o Chapter 7, “Treatments for Mood Disorders: So-Called
“Antidepressants” and “Mood Stabilizers” (pp. 283-338)
American Psychiatric Association. (2022). Diagnostic and statistical manual of
mental disordersLinks to an external site. (5th ed., text
rev.). https://go.openathens.net/redirector/waldenu.edu?url=https://dsm.psy
chiatryonline.org/doi/book/10.1176/appi.books.9780890425787
Howland, R. H. (2008a). Sequenced Treatment Alternatives to Relieve
Depression (STAR*D). Part 1: Study design. Journal of Psychosocial Nursing
and Mental Health ServicesLinks to an external site., 46(9), 21–24.
https://doi.org/10.3928/02793695-20080901-06
Howland, R. H. (2008b). Sequenced Treatment Alternatives to Relieve
Depression (STAR*D). Part 2: Study outcomes. Journal of Psychosocial
Nursing and Mental Health ServicesLinks to an external site., 46(10), 21–24.
https://doi.org/10.3928/02793695-20081001-05
Lorberg, B., Davico, C., Martsenkovskyi, D., & Vitiello, B. (2019). Principles in
using psychotropic medication in children and adolescents. In J. M. Rey & A.
Martin (Eds.), IACAPAP e-textbook of child and adolescent mental healthLinks
to an external site..
https://iacapap.org/_Resources/Persistent/45bdffb25befc353c9f61988e821
05029504ab85/A.7-Psychopharmacology-2019.1.pdf
Magellan Health. (2013). Appropriate use of psychotropic drugs in children
and adolescents: A clinical monographLinks to an external site..
http://www.magellanhealth.com/media/445492/magellanpsychotropicdrugs-0203141.pdf
Poznanski, E. O., & Mokros, H. B. (1996). Child depression rating scale—
RevisedLinks to an external site.. Western Psychological Services.
Rao, U. (2013). Biomarkers in pediatric depression. Depression & AnxietyLinks
to an external site., 30(9), 787–791. https://doi.org/10.1002/da.22171
Yasuda, S. U., Zhang, L. & Huang, S.-M. (2008). The role of ethnicity in
variability in response to drugs: Focus on clinical pharmacology
studies. Clinical Pharmacology & TherapeuticsLinks to an external site., 84(3),
417–423.
https://web.archive.org/web/20170809004704/https://www.fda.gov/downl
oads/Drugs/ScienceResearch/…/UCM085502.pdf
Medication Resources
•
U.S. Food & Drug Administration. (n.d.). Drugs@FDA: FDA-approved
drugsLinks to an external site..
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Note: To access the following medications, use the Drugs@FDA resource. Type the
name of each medication in the keyword search bar. Select the hyperlink related to the
medication name you searched. Review the supplements provided and select the
package label resource file associated with the medication you searched. If a label is not
available, you may need to conduct a general search outside of this resource provided.
Be sure to review the label information for each medication as this information will be
helpful for your review in preparation for your Assignments.
Review the following medications:
•
•
•
•
•
•
•
•
•
•
•
amitriptyline
bupropion
citalopram
clomipramine
desipramine
desvenlafaxine
doxepin
duloxetine
escitalopram
fluoxetine
fluvoxamine
•
•
•
•
•
•
•
•
•
•
•
imipramine
ketamine
mirtazapine
nortriptyline
paroxetine
selegiline
sertraline
trazodone
venlafaxine
vilazodone
vortioxetine
NURS_6630_Week_Assignment_Rubric
Criteria
This criterion is
linked to a Learning
OutcomeDevelop a
patient medication
guide for treatment of
depressive disorders
in a vulnerable
population you
selected. • Depressive
disorder causes and
symptoms • How
depression is
diagnosed for the
vulnerable population
of your choice
Ratings
20 to >17.0 pts
Excellent Point range: 90–
100
Discussion includes
Depressive disorder causes and
symptoms; Discussion
includes how depression is
diagnosed for the chosen
vulnerable population. The
response accurately and clearly
explains in detail the specific
patient factors that impact
decision making when
prescribing medication for this
patient.
17 to >15.0 pts
Good Point range:
80–89
Discussion is vague
regarding Depressive
disorder causes and
symptoms;
Discussion is vague
on how depression is
diagnosed for the
chosen vulnerable
population.
15 to >13.0 pts
Fair Point range:
70–79
Discussion is vague
regarding Depressive
disorder and missing
causes and/or
symptoms; Discussion
is vague on how
depression is
diagnosed for the
chosen vulnerable
population.
13 to >0 pts
Poor Point ran
69
Discussion is in
regarding Depre
disorder and mi
causes and/or
symptoms; Disc
is missing and/o
inaccurate on ho
depression is di
for the chosen
vulnerable popu
Order an Essay Now & Get These Features For Free:
Turnitin Report
Formatting
Title Page
Citation
Outline
